Key result
Co-administration of telmisartan significantly increased the area under the curve (AUC) of sorafenib by 77.7%, and multiple doses of donafenib increased the AUC of telmisartan by 0.97-fold in rats.
Why the study?
Telmisartan is often co-prescribed to attenuate sorafenib- or donafenib-induced hypertension, but the pharmacokinetic interactions between these agents are not well understood.
Does co-administration of telmisartan with sorafenib or donafenib alter their pharmacokinetic profiles in male Sprague-Dawley rats?
Does co-administration of telmisartan with sorafenib or donafenib alter their pharmacokinetic profiles in male Sprague-Dawley rats?
Significant pharmacokinetic interactions exist between telmisartan and sorafenib or donafenib in rats, which may necessitate dosage adjustments when co-administered for targeted therapy-induced hypertension.
Answers are grounded in this paper and cite their sources.
May warrant caution with co-administration; leaves open human pharmacokinetic confirmation.
Background: Sorafenib and lenvatinib play a significant role as small molecule targeted drugs in the treatment of advanced hepatocellular carcinoma. However, both drugs are most commonly associated with hypertension as a side effect, frequently needing antihypertensive treatment. Telmisartan, an antagonist of angiotensin II receptor, can attenuate sorafenib- or donafenib-induced hypertension. In clinical settings, sorafenib or donafenib is often prescribed alongside telmisartan, but the pharmacokinetic interactions between donafenib and telmisartan, as well as sorafenib and telmisartan, are not well understood. Therefore, this study aimed to evaluate these pharmacokinetic interactions in male Sprague-Dawley (SD) rats. Methods: The animals were divided into seven groups (n = 6) and treated with sorafenib, donafenib, or telmisartan as monotherapy (groups I–III), multi-dose sorafenib or donafenib with single dose telmisartan (groups IV and V), or multi-dose telmisartan with single dose sorafenib or donafenib (groups VI and VII). The levels of drugs in rat plasma were quantified using ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS). Results: Multiple doses of donafenib resulted in a 0.97-fold ( P =0.010) increase in the area under the plasma concentration–time curve (AUC) of telmisartan and a 57.3% ( P =0.038) and 45.6% ( P =0.032) decrease in the apparent clearance (CL z/F ) and the apparent volume of distribution (V z/F ) of telmisartan, respectively. Telmisartan resulted in a decrease in donafenib exposure; however, this effect was not statistically significant. The pharmacokinetic characteristics of sorafenib were significantly altered when it was co-administered with telmisartan. In particular, the AUC value and the maximum plasma concentration (C max ) increased by 77.7% ( P < 0.001) and 60.9% ( P < 0.001), respectively, whereas V z/F (50.4%, P =0.008) and CL z/F (46.0%, P =0.006) were significantly decreased. However, sorafenib did not affect the pharmacokinetic characteristics of telmisartan. Conclusion: The results demonstrated potential interactions between telmisartan and sorafenib or donafenib, which may guide dosage adjustment and prevent toxic effects in individual patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied Pharmacokinetic interactions (n=42). Telmisartan co-administered with Sorafenib or Donafenib vs. Monotherapy (sorafenib, donafenib, or telmisartan alone) was evaluated on Area under the plasma concentration-time curve (AUC0-t) of sorafenib (77.7% increase, p=<0.001). Co-administration of telmisartan significantly increased the area under the curve (AUC) of sorafenib by 77.7%, and multiple doses of donafenib increased the AUC of telmisartan by 0.97-fold in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: